Some patients with pharmacoresistant epilepsy undergo therapeutic resection of the epileptic focus. At least 12 large-scale microarray studies on brain tissue from epilepsy surgery have been published over the last ten years, but they have failed to make a significant impact upon our understanding of pharmacoresistance because: (1) doubts have been raised about their reproducibility, (2) only a small number of the gene expression changes found in each microarray study have been independently validated, and (3) the results of different studies have not been integrated to give a coherent picture of the genetic changes involved in epilepsy pharmacoresistance. To overcome these limitations, we (1) assessed the reproducibility of the microarray studies by calculating the overlap between lists of differentially regulated genes from pairs of microarray studies and determining if this was greater than would be expected by chance alone; (2) used an inter-study cross-validation technique to simultaneously verify the expression changes of large numbers of genes; and (3) 
Introduction
Epilepsies are among the most common neurological disorders, affecting up to 1% of the population (1) . Most patients with epilepsy become seizure-free with antiepileptic drug (AED) therapy. However, approximately 30% of epilepsy patients have a medically intractable condition even if treated with various AEDs at maximal dosages either alone or in combination (2) . A subset of patients with intractable epilepsy have the potential for a surgical cure, most commonly those with hippocampal sclerosis (3) . Surgical samples from patients with intractable epilepsy provide a unique opportunity to directly analyse the human epileptic focus in order to determine the causes of pharmacoresistance.
Many different causes of pharmacoresistance have been postulated, for example dysregulation of multidrug transporters (4), reduced drug-target sensitivity (4), increased neuronal apoptosis (5), cytoskeletal alterations (6) , and reorganization of neuronal networks (7) . The exact molecular mechanisms underlying pharmacoresistance, however, are still poorly understood. Alterations in the expression of a large number of genes are thought to be responsible, but most of the numerous genes that participate in the development of pharmacoresistance in epilepsy remain unidentified.
To date, the vast majority of studies on samples from epilepsy surgery have focused primarily on a number of selected candidate genes. However, these techniques are not suitable for dissection of multiple interacting molecular pathways or screening potential molecular abnormalities when the list of candidate genes is extensive. In contrast, large-scale microarray studies offer the advantage of assaying gene expression in a comprehensive, unbiased and genome-wide fashion. Analysing the expression profile of many genes simultaneously in large-scale expression studies, without making prior assumptions about candidate genes, allows the identification of new genes and molecular pathways associated with the condition. There have been at least 12 published large-scale gene expression studies on tissue from epilepsy surgery in the last ten years (see below). However, they have failed to make a significant impact on our understanding of the causes of pharmacoresistance. In our view, this failure is due to several reasons. results. Before drawing conclusions about the differential expression of a specific gene, it is thought necessary to demonstrate independent experimental validation (8) using techniques such as reverse transcription-polymerase chain reaction. Therefore, it is commonplace to use the microarray as a screening tool, then to validate a few chosen genes for additional investigation. However, this methodology under-uses the 'depth' inherent in the original microarray dataset and is prone to missing potentially important genes and networks. Hence, experts (9) have proposed using multiple microarray datasets that address similar hypotheses to simultaneously cross-validate all of the positive results. This inter-study cross-validation approach has been adopted in the present work.
Second, doubts have been raised about the reproducibility of microarray studies in epilepsy (10) (11) (12) . It has been suggested that the majority of changes in gene expression are specific to laboratory or experimental conditions with very few genes demonstrating changes in more than two publications (12) . Third, the results of different microarray studies have not been integrated to give a coherent picture of the genomic changes involved in epilepsy pharmacoresistance.
We believe that the above problems can be overcome by testing the validity and reproducibility of the individual microarray studies and by performing an integrative analysis of all available microarray results. We are aware of only two previous published reviews which have included microarray studies on non-cancerous brain tissue from epilepsy surgery (10, 12) . However, neither of these reviews included all currently available microarray studies on brain tissue from epilepsy surgery; in fact, the study by Lukasiuk and Pitkänen, (2004) includes only one human microarray study, and the study by Wang et al., (2010) includes only three human large-scale gene expression studies. These reviews found a very small number of genes that showed similar expression profiles and, hence, found it difficult to draw robust conclusions about the possible mechanism(s) of pharmacoresistance in epilepsy. In the present work, we have performed an integrative analysis of all available microarray studies on non-cancerous brain tissue from epilepsy surgery with the aim of identifying novel and important genes and networks that play a role in pharmacoresistance.
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Results
Gene lists
We found 12 published large-scale genome-wide gene expression profiling studies on non-neoplastic tissue from epilepsy surgery (11, (13) (14) (15) (16) (17) (18) (19) (20) . Gene lists were available for nine genome-wide gene expression studies, and these were included in the present review. Seven studies published one differentially regulated gene list each. However, Lee et al., (2007) and van Gassen et al., (2008) used more than one type of control tissue and published more than one list of differentially regulated genes each. Lee et al., (2007) used two types of controls: (1) histologically normal CA1 from patients with 'paradoxical temporal lobe epilepsy (PTLE)', citing the evidence that the poor seizure free outcome (44%) in PTLE following hippocampectomy suggests that the hippocampus is unlikely to be epileptogenic in this group, and (2) histologically normal CA1 tissue from 'mass-associated temporal lobe epilepsy (MaTLE)' where the mass lesion was outside the hippocampus, citing the evidence that mesial temporal lobe epilepsy (MTLE) granule cells are hyperexcitable while those in MaTLE are not. The authors presented two lists of differentially regulated genes: (1) genes regulated by 1.5 fold or more for both MTLE vs. PTLE and MTLE vs. MaTLE, and (2) genes regulated 1.5 fold or more when MaTLE and PTLE were considered replicates of non-sclerotic hippocampi. Regulated genes from both lists were integrated into the current systematic review, giving a list of 758 unique genes that could be mapped to Entrez gene numbers. Similarly, van Gassen et al., (2008) , compared slices of sclerosed hippocampus with histologically normal hippocampal slices from patients with MTLE but no hippocampal sclerosis (HS). However, van Gassen et al., (2008) also compared normal hippocampal autopsy samples with histologically normal hippocampal slices from patients with MTLE but no HS. The non-HS MTLE and HS groups were found to share a large group of differentially expressed genes when compared to the autopsy group, and there was a significant overlap between functional gene classes affected in non-HS MTLE and HS groups when compared to autopsy samples. Hence, the autopsy vs non-HS MTLE gene list was also deemed appropriate for inclusion in the current systematic review. In total, van Gassen et al., (2008) Regulated genes from all three lists were integrated into the current systematic review. 24 genes had conflicting changes in expression (downregulated in one list but upregulated in another) and were excluded, leaving 521 unique genes.
Study characteristics
The nine included studies had sample sizes ranging from six to 60. All studies used test tissue from the temporal lobe, and all but three studies (14, 16, 20) used test tissue from the hippocampus. Gene expression profiling platforms used included one-channel microarrays, two-channel microarrays and Serial Analysis of Gene Expression ( Table 1 ). The smallest microarray chip used was able to assay up We assessed the methodological quality of the included studies. One limitation applies to all the studies: no power calculations were performed to determine the appropriate sample size. In addition, each study had specific methodological strengths and weaknesses. For example, van Gassen et al.
(2008) performed a like-for-like tissue comparison, detailed probe-and array-level quality control procedures, corrected p-values for multiple testing, and deposited MIAME-compliant data in a publically-accessible repository, but used a modest sample size and applied no fold change criterion to differentially regulated gene lists. On the other hand, Xiao et al. (2008) used a large sample size and applied appropriate fold change criterion, but did not perform a like-for-like tissue comparison, or detail probe-and array-level quality control procedures, or perform correction for multiple testing, or deposit their data in a public database. Table 2 lists the criteria used to assess methodological quality, and the quality assessment outcomes for the individual studies.
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Study heterogeneity
There was heterogeneity within the studies and the number of genes shown to be regulated in the individual studies varied widely ( Table 1 ). The largest parts of this variation can be explained by:
1. The number of genes that can be assayed by the different arrays (see above).
2. The widely differing criteria used to define statistically significant change in gene expression ( Table 2 ).
Other sources of heterogeneity were:
1. Differences in sample handling and RNA extraction techniques.
2. Different gene expression profiling platforms used.
3. Varying microarray data normalization procedures.
4. Test tissue used: Sclerosed hippocampus was used by most studies, but other anatomical regions and other pathologies were also employed by some studies (Table 1) . While acknowledging the heterogeneity within the studies, it is important to note that there is also an underlying commonality in the design of the studies: comparing gene expression between pharmacoresistant epileptic brain samples and non-epileptic or pharmacoresponsive brain samples.
Although some of the differentially expressed genes identified in individual studies will be specific to the histological characteristics of the tissues being compared and to laboratory conditions, a significant subset of genes in each list represents the universal genetic changes linked with pharmacoresistance. As validation of this concept, we determined the size of the overlap between pairs of gene lists and calculated if this size was greater than would be expected by chance alone (see 'Data validation' section below). To test the validity of the list of genes differentially regulated in only one study, we compared this to a list of all human genes and human homologues of mouse and rat genes from CarpeDB (www.carpedb.ua.edu), a dynamic continuously-updated epilepsy genetics database. Of the 278 genes thus extracted from CarpeDB, 54 overlapped with our list of genes differentially regulated in only one study. This overlap was statistically significant (FDR P=1.2x10
−24
).
Overlapping gene lists
Genes differentially expressed in three or four studies are listed in Table 3 . Prominently represented in these two lists are genes involved in neuroinflammation, in the control of synaptic transmission and in the restructuring of neuronal networks-specific examples are discussed below (see Discussion section). Genes differentially regulated in one study or two studies are shown in Supplementary Table   2 .
Gene Ontology Enrichment Analysis
The top 25 significantly enriched GO terms are listed in Table 4 
Pathway Analysis
The top 25 significantly enriched canonical pathways and networks are shown in Table 5 . Details of all enriched pathways and networks are provided in Supplementary Table 3 . An explanation of how some of the most significant pathways and networks might contribute to the development of pharmacoresistance is presented in the Discussion section.
Comparison with an Alzheimer's disease brain microarray dataset
To counter arguments that the genetic changes highlighted by this analysis are non-specific and could be found in any brain pathology, we compared our results with the results of a microarray study on AD-affected hippocampi. From the AD study, we extracted 3738 unique genes which could be mapped to Entrez IDs. Ingenuity Systems Pathway Analysis was used to determine significantly enriched canonical pathways from this gene list. In Table 6 , we compare the top ten canonical pathways from the AD and the epilepsy datasets which convincingly demonstrated that there was no overlap between the identified top canonical pathways for the two datasets. In addition, the processes performed by the canonical pathways were also very different. For example, the top five canonical pathways in the pharmacoresistant epilepsy dataset are related to restructuring of neuronal networks (cholecystokinin signalling), modulation of synaptic transmission (synaptic long term potentiation, neuropathic pain signalling), and neuroinflammation (semaphorin signalling, chemokine signalling), while the top five pathways in the AD dataset are related to protein degradation (protein ubiquitination pathway), energy metabolism (mitochondrial dysfunction, oxidative phosphorylation), and translational regulation (regulation of eIF4 and p70S6K signalling, eIF2 signalling). ) with a study comparing sclerosed CA1 with histologically normal CA1 from MTLE patients using an Affymetrix U133A microarray .
In addition, a significant number of the 1174 genes which were shown to be differentially expressed in only one study (a 'non-corroborated gene set') are also likely to be relevant to epileptogenesis and pharmacoresistance. To demonstrate this we compared the non-corroborated gene set with CarpeDB, a dynamic continuously-updated epilepsy genetics database. Of the 278 genes extracted from CarpeDB, 54 genes overlap with our non-corroborated gene set. This overlap is highly significant (FDR=1.2x10 −24 ). This suggests that the non-corroborated gene list is also an important data source which should be appropriately studied and interpreted (see below).
It is of course possible that some of the gene expression changes identified in this analysis are the consequence, rather than the cause, of refractory seizures; this limitation is inherent in large-scale gene expression profiling studies and, hence, also in this analysis. The causative role of candidate genes identified as potentially playing a part in the development of pharmacoresistance will need to be established with further investigation, such as electrophysiological studies in hippocampal neuronal cultures or studies in rodent epilepsy models where the expression of the relevant gene has been appropriately altered. Another limitation which applies to all transcriptomic studies, and also to this analysis, is that mRNA concentration may not be a predictor of protein abundance or activity because of the many processes downstream of mRNA synthesis (for example, alternative mRNA splicing and microRNA regulation) that may affect the total amount and activity of protein in tissue. It should also be noted that we have chosen not to include in the present work gene expression profiling studies on animal models of epilepsy as we are not aware of any microarray studies done on models of intractable epilepsy, such as the pharmacoresistant amygdale-kindled rat (21) . Hence, the available gene expression profiling studies on animal models of epilepsy do not reflect the phenotype of interest.
Data integration
Microarray technology has become an important tool for biological research, but it can suffer from both low sensitivty and high false positive rates (9) . One way of overcoming these limitations is to use meta-analysis methods that integrate the results of separate microarray studies. Meta-analysis is a classical statistical methodology for combining results from different studies addressing the same scientific questions, and has recently been applied to the analysis of microarray data, increasing both the sensitivity and reliability of measurements of gene expression changes (9) . Two basic metaanalysis methods have been applied to microarray studies: (1) combining p-values for each gene from the individual studies to estimate an overall p-value for each gene across all studies (9) , and (2) integrating effect size estimates to obtain an overall estimate of the average effect size (22) . However, the majority of studies included in this review did not provide the basic information that would allow either meta-analysis method to be applied. This being the case, we integrated the gene lists provided by each study to generate lists of genes consistently regulated in two, three or four studies. This integrative technique successfully improved the reliability of the regulated gene lists, without enhancement of the sensitivity. Hence, the 233 genes shown in this review to overlap between two or by guest on http://hmg.oxfordjournals.org/ Downloaded from more studies are a 'corroborated gene set' unlikely to be specific to the histological characteristics of the tissues being compared or to laboratory conditions, and most likely to represent universal genetic changes linked with epileptogenesis and pharmacoresistance. For GO term enrichment analysis, canonical pathway analysis and network analysis, we included both the corroborated and noncorroborated gene sets. This is because a significant number of the non-corroborated genes are also likely to be relevant to pharmacoresistance, as demonstrated by the significant overlap with the CarpeDB database. Further, in terms of genes shown to be regulated in single studies, we took the view that different genes validate each other if they are significantly enriched together in a GO term category, canonical pathway or an interaction network.
What does this analysis tell us about the mechanism of pharmacoresistance?
Current theories on pharmacoresistance in epilepsy include the multidrug transporter (MDT) hypothesis, the drug target hypothesis, and the inherent severity hypothesis (23) . It has recently been suggested that these processes are likely to act not in a mutually exclusive manner, but rather an integrated manner, to cause pharmacoresistance (23) . The current analysis supports this view, suggesting that all three hypotheses may be important. However, much of the integrated evidence generated by this analysis is weighted towards the intrinsic severity hypothesis.
MDT hypothesis
According to the MDT hypothesis, pharmacoresistance results from impaired drug penetration into the epileptic focus secondary to dysregulation of drug transporters (24) . Studies on the role of MDTs in pharmacoresistant epilepsy have, hence far, been limited to a small number of selected adenosine triphosphate-binding cassette (ABC) transporters, with a predominant focus on ABCB1 (25) . Five ABC transporters were found to be upregulated in the studies included in this analysis: ABCA6, ABCA8, ABCC4, ABCA2 and ABCB6. Of these five transporters, only ABCC4 has previously been studied in pharmacoresistant epilepsy (26) (27) . The identification in this study of hitherto overlooked MDTs suggests that the search for drug transporters relevant to epilepsy pharmacoresistance needs to be expanded beyond the select few candidates which have been studied so far. It is interesting to note that ABCB1, which has been the focus of the majority of research on the role of MDTs in epilepsy pharmacoresistance (28), was not shown to be regulated in any of the included studies, even though a probe for ABCB1 was present on the arrays of at least four of the nine studies. The role non-ABC drug transporters may play in epilepsy pharmacoresistance is also much neglected. For example, solute carrier (SLC) group of membrane transporters have been shown to play a role in cancer pharmacoresistance (29) , but their potential role in epilepsy pharmacoresistance has not been studied.
Twenty-seven different SLC transporters were shown to be dysregulated in the studies included in this analysis.
Drug target hypothesis
According to the drug target hypothesis, pharmacoresistance is caused by the modification of one or more drug target molecules.
An important AED drug target is the voltage-gated sodium channel. These channels consist of α and β subunits. To date, nine -subunits and four -subunits have been identified. It has been suggested that in pharmacoresistant epilepsy subunit composition of these channels is altered, such that the expression of AED-insensitive subunit combinations is promoted. The SCN1A subunit gene has been the focus of most research so far (30) . This analysis showed that the expression of SCN2A, SCN3A, SCN3B and SCN8A was also altered in pharmacoresistant epilepsy. SCN2A was shown to be downregulated in two different microarray studies included in this analysis. In support of this finding, SCN2A was also found to be downregulated in epileptic foci in a radioactive in situ hybridisation study (31) . In addition, two different SCN2A polymorphisms have been reported to be associated with epilepsy pharmacoresistance (32) (33) . The role of SCN2A, and the other subunits identified in this analysis, should be confirmed in future studies.
Another important AED target is the GABA A receptor (34) . The pharmacological properties of GABA A receptors depend on the combination of subunits of which there are more than 20 to choose from (35) . Three GABA A receptor subunit genes were shown to be downregulated in the studies included in this analysis: GABRA5, GABRB3 and GABRG2. GABRA5 was downregulated in four by guest on http://hmg.oxfordjournals.org/ Downloaded from of the included studies. Using immunohistochemical labelling, Bethmann et al., (2008) showed that GABRA5 subunit protein expression in the hippocampi of antiepileptic drug resistant rats was significantly lower than in responsive rats (36) . Bonin et al., (2007) have shown that the depolarizing current required to generate an action potential was two-fold greater in neurons from wildtype than from GABRA5 knockout mice (37) . Phenytoin (38) and carbamazepine (39) have been shown to upregulate GABRA5, and this has been suggested to be involved in their antiepileptic mechanism.
GABRA5-selective inverse agonists have been shown to have convulsant or proconvulsant effect in mice in a dose-dependent manner and proportional to the extent of GABRA5 efficacy (40) . The current analysis reveals strong evidence of downregulation of GABRA5 in human epileptic tissue.
Further studies are needed to look for associations between polymorphisms in the GABRA5 gene and pharmacoresistance, and for ways to reverse the downregulation of GABRA5.
Intrinsic severity hypothesis
The observation that a high frequency of seizures prior to onset of treatment is a prognostic signal of increased severity and future drug failure suggests that common neurobiological factors may underlie both disease severity and pharmacoresistance (23) . A number of processes are thought to contribute to the development of pharmacoresistant epilepsy through promoting severity: neuroinflammation, enduring increases in excitatory synaptic transmission, changes in GABAergic inhibition, neuronal cell death, and the development of aberrant innervation patterns in part arising from reactive axonal growth (41) . Although this review lends supports to all these processes playing a part, three basic themes were most prominently overrepresented in the gene list assembled: What follows is a brief summary of the aforementioned three themes, as represented by our analysis.
From the themes, we highlight novel and important genes and pathways. This is not a comprehensive précis, and we invite readers to peruse the gene lists and enriched GO terms, pathways and networks to find other genes, pathways and networks of interest.
Neuroinflammation
It is being increasingly recognised that inflammation plays an important role in the pathogenesis of epilepsy (42) . The role of chemokine-and semaphorin-induced inflammation in the development of refractory epilepsy is little studied (43) . Our analysis suggests that chemokine and semaphorin signalling plays a significant role in epilepsy pharmacoresistance. We have also identified particular chemokines and semephorins that are potentially important therapeutic targets.
Chemokines
The chemokine signalling canonical pathway was shown to be dysregulated in our analysis, and the the chemokine CCL2 and chemokine target Inhibin β-A were prominent in our gene list. Chemokines can induce neuronal hypersynchronization and neuronal epileptiform activity (44) (45) (46) , leading to seizure generation in animal models of epilepsy (47) . CCL2 upregulation has been linked to increased susceptibility to seizures in a 'two-hit' seizure model in rats (48) , and valproic acid has been shown to downregulate CCL2 mRNA in rat brain (49) . Inhibin β-A is a member of the transforming growth factor-β superfamily (50) In addition, the canonical pathway of chemokine receptor CXCR4 was dysregulated. Increased expression of CXCR4 allows for increased CXCL12 binding. CXCL12 induces a slow inward current followed by a spontaneous synaptic activity via ionotropic glutamatergic receptors (53) , and induces microglia to release TNFα, which potentiates prostaglandin-dependent Ca ++ activation and glutamate release (13) . Other dysregulated chemokines in our analysis were CCL3, CCL4, CCL28, CCL3L1, CX3CL1 and CXCL14.
Semaphorin Signaling in Neurons
The current review reveals the upregulation of the semaphorin pathway (Figure 1 
Modulation of synaptic transmission
The cellular component ontology term enrichment shows that some of the most important processes in the development of pharmacoresistance are occurring in membrane-bound vesicles and at the pre-and post-synaptic terminal. The most significant biological processes are cellular cation homeostasis, synaptic transmission and synaptic plasticity. The enriched gene ontology terms suggest that the most important molecular functions in the development of pharmacoresistance are calcium transport and signalling, and transporter activity. Therefore, changes in calcium signalling and in synaptic structure and function were shown to be important in our analysis. (65) which is the core of the synaptic release machinery (66), was downregulated in three studies and is particularly deserving of further study. Perturbations of the complexin proteins causes an increase in spontaneous and asynchronous release of neurotransmitter in some types of synapses, indicating an inhibitory role of the proteins (65) . Hence, the reduction in complexin 2 expression in the epileptic focus, as demonstrated in this review, could lead to increases in excitatory synaptic transmission, and deserves further study.
Restructuring of neuronal networks
The gene ontology enrichment analysis suggests that some of the most important processes in the development of pharmacoresistance are occurring in the cytoskeleton, the dendrite, the axon, and the growth cone. Some of the most significant biological processes are apoptosis, cytoskeletal organization, neuronal development and differentiation, axonal and dendritic morphogenesis, and one of the most important molecular functions in the development of pharmacoresistance is cytoskeletal function. In support of this, Network 2 reveals dysregulation of proteins involved in apoptotic important, yet understudied, role in the development of aberrant neuronal networks.
Cholecystokinin Signaling
CCK controls the perisomatically targeting inhibitory interneurons of the hippocampus (67) . In kindling rodent models of epilepsy, there is a reduction of GABA-evoked inhibitory post-synaptic currents in the hippocampus, and this loss corresponds with a reduction in CCK-labelled interneurons (68) . In humans, the CCK content of cortical tissue from which active epileptic spiking was recorded at the time of surgery was significantly decreased in comparison to tissue samples from patients in whom the lateral temporal cortex was electrographically free of epileptiform spikes (69) . CCK may have anticonvulsant and neuroprotective properties. Pretreatment of hippocampal slices with sulfated CCK blocked the effect of kainic acid on synaptic transmission (70) . Seizures in a breed of rat with congenital audiogenic seizure were suppressed by cholecystokinin octapeptide injected intraperitoneally (71) and by intracerebral injection of a CCK gene vector (72) . Seizures induced by picrotoxin and electroshock are inhibited by intracerebroventricular administration of cholecystokinin in rats (73) . There is also a positive influence of CCK on the anticonvulsant efficacy of vigabatrin (74) . CCK, therefore, is another potential therapeutic agent that should be further studied. 
Methods
Inclusion Criteria
We aimed to include all large-scale gene expression profiling studies fulfilling the following criteria:
1. Recruited patients had clearly defined refractory epilepsy.
2. The epileptic focus was ascertained on the basis of clinical features, electroencephalography, brain imaging, and post-operative tissue histology as necessary.
6. Minimum Information About a Microarray Experiment (MIAME)-compliant data was provided or, at the very least, a list of significantly regulated genes and the direction of change (up-or down-regulated) was provided.
Search Strategy
We searched records in Medline and Embase, without language restriction, between January 1987 and January 2011. Large-scale microarray technology was first described in 1987 (Kulesh et al., 1987);
hence 1987 formed the starting point for our search. We used the following search terms: (1) "geneexpression profiling", or (2) "microarray analysis", or (3) "transcription profiling", or (4) "cluster analysis", or (5) "Affymetrix", (6) or "GeneChip", or (7) "serial analysis of gene expression", or (8) "SAGE", and (1) "epilepsy", or (2) "TLE", or (3) "MTLE". We also hand-searched the reference lists of every primary study, previously published systematic reviews and other review articles.
We also searched public repositories of microarray datasets: Array Express 
Data Gathering: Raw Data
We found 12 published genome-wide gene expression profiling studies on non-neoplastic tissue from epilepsy surgery. Raw data for the study by Ozbas-Gerceker et al., (2006) was available from the GEO database. Minimum Information About a Microarray Experiment (MIAME)-compliant data for the study by van Gassen et al., (2008) was available on the ArrayExpress database. MIAMEcompliant data was not publically available for any other study. The corresponding author from each of the remaining ten studies was contacted to request MIAME-compliant microarray results data, but by guest on http://hmg.oxfordjournals.org/ Downloaded from MIAME-compliant data was not provided by any author. As raw data was only available for two studies performed on two entirely different platforms (Serial Analysis of Gene Expression and twochannel oligonucleotide microarray analysis), we judged that a useful integrative analysis of the raw data could not be performed, and raw data was not used in the present study. Instead, we obtained differentially regulated gene lists from individual studies, as detailed below.
Data Gathering: Gene Lists
Six studies published complete lists of all genes which were differentially regulated in epileptic tissue according to each study's individually defined criteria (11, 13, 15, (17) (18) (19) (20) Three studies did not publish a list of regulated genes and their authors did not provide this on request (75) (76) (77) , and hence were excluded from further analysis in this systematic review.
Data Integration
To allow inter-study comparison, gene identifiers from each study were converted to Entrez gene numbers, unless these were provided in the publication. Affymetrix probe numbers were converted to Entrez gene numbers using NetAffx Analysis Center (www.affymetrix.com/analysis). All other gene identifiers were converted to Entrez gene numbers using MatchMiner (build 137, discover.nci.nih.gov/matchminer).
For each gene list, changes in gene expression were changed to a binary score: any gene up-regulated was given a score of +1, while any gene down-regulated was given a score of −1. The nine lists of regulated genes from the nine included studies were integrated in a MS Excel spreadsheet. 42 genes were excluded because of conflicting scores (that is, they were down-regulated in one study but upregulated in another), leaving 1407 regulated genes in the integrated list incorporating all included studies. The total score was calculated for each gene. lists from the included studies were tested in pairs in this manner. In addition, to test the validity of the list of genes differentially regulated in only one study, we compared this to a list of all genes from CarpeDB (www.carpedb.ua.edu), a dynamic continuously-updated epilepsy genetics database. We extracted the human genes in the CarpeDB database. In addition, we extracted the rat and mouse genes and mapped them to human homologues using ConceptGen. 278 CarpeDB human, mouse and rat genes in total mapped to ConceptGen.
Gene Ontology Enrichment Analysis
Gene ontology (GO) terms enrichment analysis was performed in the Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 (david.abcc.ncifcrf.gov). DAVID performs an enrichment test based on the EASE score, and a False Discovery Rate <0.05 is deemed significant. For biological process and cellular component terms, there were a large number of enriched broad GO terms, which made practical interpretation difficult. Hence, for biological process and cellular component domains, 'Go Fat' analysis was performed. Go Fat filters the broadest terms so that they do not overshadow the more specific terms.
Pathway Analysis
Ingenuity Systems (www.ingenuity.com) Core Analysis was used to determine significantly enriched canonical pathways and to build significantly enriched networks from the full list of differentially regulated genes. The significance of the association between our data set genes and the canonical by guest on http://hmg.oxfordjournals.org/ Downloaded from pathways was measured in two ways: (1) a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway is displayed, and (2) a Fischer's exact test was used to calculate a p-value, determining the probability that the association between the genes in the data set and the canonical pathway was explained by chance alone. Networks were ranked by a score: the higher the score, the lower the probability of finding the observed data set genes in a given network by chance. The score takes into account the number of data set genes and the size of the network, and is the negative log of the p-value.
Comparison with an Alzheimer's Disease Brain Microarray Dataset
To counter arguments that the genetic changes highlighted by this analysis are non-specific and could be found in any brain pathology, we compared our results with the results of a large-scale gene expression profiling study on brain samples from 34 individuals with Alzheimer's disease (AD) (80) . 
